Recently, Cipla was also ranked one of the most sustainable healthcare companies in the Dow Jones Sustainability Emerging Markets Index. With the aim of reaching non-fossil fuel share of 40% by 2030, in January 2021, Cipla became the first pharmaceutical company in Maharashtra to invest in group captive open access solar power project of 30 MW capacity, spread across 115 acres.
This has contributed to Cipla’s decarbonizing goals, with the company now sourcing ~25% of its energy from renewable sources in the current year.
Cipla is also a constituent of the MSCI All Country World Index (ACWI) and has an ESG Rating of BB; as well as a constituent of FTSE4Good Index Series for the three consecutive years.
Cipla Limited said that it has been recognised as a“Challenger in Mega Large Business Pharma Sector” by Frost & Sullivan and TERI’s Sustainability 4.0 Awards. This is a testimony to its continuous efforts in the Environment, Social & Governance (ESG) space as a leader in the pharma industry.
Sharing her thoughts on this award, Geena Malhotra, Global Chief Technology Officer at Cipla said, “Sustainability is at the core of Cipla and it brings us immense pride to see that our efforts and commitment towards the Company’s sustainability agenda is being recognized. We have miles to go in this journey that we have embarked upon, however, since the start we have aimed to be purposeful in all our endeavors.”
“We will always continue to contribute to the Sustainable Development Goals (SDGs) through products, processes and philanthropic activities that place our stakeholders at the heart of value creation.” Further said.
